CAMBIO DE DISCURSO : LA SECOND-LINE SCLC-ES TRAS EL FIASCO DE LA FASE III LAGOON YA MEJOR NI NOMBRARLA...CAMBIAMOS DISCURSO A MANTENIMIENTO EN FIRTS-LINE Y PASAMOS DEL VIAL DE 4 Mg AI VIAL DE 2 Mg .//. JazzPharma TO WITHDRAW LURBINECTEDIN WITH US_FDA IN SECOND-LINE SCLC-ES...EN ESPAÑA NO SE HAN ENTERADO AÚN...SI NO EXISTIERA IMFORTE...AHORA MISMO PHARMAMAR ESTARÍA ANTE UNA GRAVE SITUACIÓN ... 2 DE OCTUBRE DE 2028 ... ES LA FECHA MÁS TEPMPRANA PARA LA POSIBLE ENTRADA DE GENÉRICOS .
21 junio 2007
19 junio 2007
18 junio 2007
Joan Vericat , de NeuroPharma , en Euronanoforum ( Alemania ) 19 al 21 Junio . Nanotechnology in Life .
Poster :
P-C10
SAFETY ASSESSMENT OF NANOMEDICINES/NANODEVICES: CURRENT GUIDELINES ARE SUFFICIENT TO ENSURE SAFETYJoan-Albert Vericat, Isolde Anglade, Nicolas Fabre Neuropharma SA, Madrid (Spain)
P-C10
SAFETY ASSESSMENT OF NANOMEDICINES/NANODEVICES: CURRENT GUIDELINES ARE SUFFICIENT TO ENSURE SAFETYJoan-Albert Vericat, Isolde Anglade, Nicolas Fabre Neuropharma SA, Madrid (Spain)
17 junio 2007
15 junio 2007
Patente EEUU , Yondelis consigue Reforzar los efectos citotóxicos del Platinum .
Combined use of Yondelis and platinum antineoplastic compounds .
Publication number: US2007128201
Publication date: 2007-06-07
Inventor: D INCALCI MAURIZIO (IT); GIANNI LUCA (IT); GIAVAZZI RAFFAELLA (IT); MARTIN MARGARITA G (ES); JUDSON IAN (GB); DONAQUE JOSE M J (ES); SESSA CRISTIANA (CH)
Applicant: PHARMA MAR S A U (ES)
Classification: - international: A61K39/395; A61K31/282; A61K31/495; A61K31/555; A61K33/24; A61P35/00; A61K39/395; A61K31/28; A61K31/495; A61K31/555; A61K33/24; A61P35/00; - European: A61K31/282; A61K31/495; A61K31/555; A61K33/24
Application number: US20040558133 20040601
Priority number(s): GB20030012407 20030529; WO2004GB02319 20040601
Abstract of US2007128201 Yondelis can be used to mitigate resistance to and potentiate the cytotoxic effects of a platinum coordination complex anti-neoplastic agent in a human cancer patient.
Publication number: US2007128201
Publication date: 2007-06-07
Inventor: D INCALCI MAURIZIO (IT); GIANNI LUCA (IT); GIAVAZZI RAFFAELLA (IT); MARTIN MARGARITA G (ES); JUDSON IAN (GB); DONAQUE JOSE M J (ES); SESSA CRISTIANA (CH)
Applicant: PHARMA MAR S A U (ES)
Classification: - international: A61K39/395; A61K31/282; A61K31/495; A61K31/555; A61K33/24; A61P35/00; A61K39/395; A61K31/28; A61K31/495; A61K31/555; A61K33/24; A61P35/00; - European: A61K31/282; A61K31/495; A61K31/555; A61K33/24
Application number: US20040558133 20040601
Priority number(s): GB20030012407 20030529; WO2004GB02319 20040601
Abstract of US2007128201 Yondelis can be used to mitigate resistance to and potentiate the cytotoxic effects of a platinum coordination complex anti-neoplastic agent in a human cancer patient.
14 junio 2007
Suscribirse a:
Entradas (Atom)